Patent · US Active

Antibodies targeting bone morphogenetic protein 9 (BMP9) and methods therefor

US10047155B2 · kind B2 · utility

2Cited by

8References

34Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Zijun Chen · Shanghai, CN
Sujun DENG · Shanghai, CN
Yun HE · Beijing, CN
Dagang Huang · Mundelein, US
Markus Kugler · Planegg, DE
Qian Li · Sydney, AU
Chris Lu · Shanghai, CN
Xiao LUO · Beijing, CN
Yongqiang Shan · Shanghai, CN
Kathrin Ulrike Tissot-Daguette · Schwanau, DE
Jing Wu · Mundelein, US

Key dates

Filing date	May 26, 2016
Grant date	Aug 14, 2018
Priority date	—
Expiry date	Aug 4, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/94
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to isolated antibodies and antigen-binding fragments thereof which bind human BMP9 and compositions and methods of use thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.